Login to Your Account

Financings NEWS

LONDON – Pherecydes Pharma SA has raised $10.3 million in a series B round, which it said will enable it to get approval for its bacteriophage manufacturing system and to make products available for treating serious antibiotic-resistant infections on a compassionate use basis.

HONG KONG – KBP Biosciences Co. Ltd. closed a $76 million series A financing to, among other things, advance its lead asset, KBP-5074, a mineralocorticoid receptor antagonist for cardiovascular disease entering phase IIb studies.

Gossamer Bio Inc., a new company looking to leverage what it called "an asset-rich in-licensing environment," has raised $100 million from Arch Venture Partners and Omega Funds to rev up operations, advance trials for its early and late-stage candidates, and further augment its pipeline.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: